FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071320908> ?p ?o ?g. }

• W2071320908 endingPage "213" @default.
• W2071320908 startingPage "206" @default.
• W2071320908 abstract "Almotriptan is a highly specific 5-HT(1B/1D) receptor agonist, which acts selectively on blood vessels of the brain. Short-term studies have demonstrated that almotriptan provides rapid, effective and reliable relief of migraine attacks, while offering excellent tolerability.To assess the long-term tolerability and efficacy of oral almotriptan 12.5 mg administered for every migraine attack over a 1-year period.A total of 762 patients treated 13,751 attacks (1-97 per patient); 61.5% of attacks were treated with one 12.5-mg dose, while for 38.5% of attacks, patients took a second dose within 24 h.Three hundred and ninety-one patients (51.3%) experienced a total of 1,617 adverse events (AEs). The majority (88.6%) of AEs were of mild-to-moderate intensity, and only 28.8% of AEs were considered to be related to the study drug. Only 2 patients experienced serious AEs possibly related to almotriptan, syncope and chest pain; both recovered without any sequelae. Patients reported at least 1 AE in 11% of attacks treated. The incidence of AEs decreased during the study. Only 6 (0.8%) study withdrawals were due to AEs considered to be related to almotriptan. Tolerability was not compromised in patients taking 2 doses of almotriptan or in those using migraine prophylactics. Patient age or sex did not influence the incidence of AEs. There was no evidence of tachyphylaxis in those patients completing the study. Pain relief at 2 h after the initial dose was achieved in 84.2% of moderate/severe attacks. Patients were pain free at 2 h after dose in 58.2% of all attacks. Older patients (> 40 years) tended to respond better than younger ones (< 40 years). Efficacy was not modified by use of migraine prophylactics or hormonal contraceptives. Efficacy measurements were consistent on treating repeated moderate/severe migraine attacks.This large, open study indicates that the new, specific 5-HT(1B/1D) agonist almotriptan, at a dose of 12.5 mg, is a well tolerated and effective treatment for migraine pain when used over a period of up to 1 year." @default.
• W2071320908 created "2016-06-24" @default.
• W2071320908 creator A5000442700 @default.
• W2071320908 creator A5015436325 @default.
• W2071320908 creator A5022276612 @default.
• W2071320908 creator A5026201062 @default.
• W2071320908 creator A5030620040 @default.
• W2071320908 creator A5040917727 @default.
• W2071320908 creator A5070261883 @default.
• W2071320908 creator A5072346701 @default.
• W2071320908 creator A5084607034 @default.
• W2071320908 date "2001-01-01" @default.
• W2071320908 modified "2023-10-16" @default.
• W2071320908 title "Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of Migraine" @default.
• W2071320908 cites W1977016605 @default.
• W2071320908 cites W1991022206 @default.
• W2071320908 cites W2058460644 @default.
• W2071320908 cites W2062761297 @default.
• W2071320908 cites W2091825976 @default.
• W2071320908 cites W2149318059 @default.
• W2071320908 doi "https://doi.org/10.1159/000052131" @default.
• W2071320908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11385257" @default.
• W2071320908 hasPublicationYear "2001" @default.
• W2071320908 type Work @default.
• W2071320908 sameAs 2071320908 @default.
• W2071320908 citedByCount "46" @default.
• W2071320908 countsByYear W20713209082013 @default.
• W2071320908 countsByYear W20713209082019 @default.
• W2071320908 countsByYear W20713209082020 @default.
• W2071320908 crossrefType "journal-article" @default.
• W2071320908 hasAuthorship W2071320908A5000442700 @default.
• W2071320908 hasAuthorship W2071320908A5015436325 @default.
• W2071320908 hasAuthorship W2071320908A5022276612 @default.
• W2071320908 hasAuthorship W2071320908A5026201062 @default.
• W2071320908 hasAuthorship W2071320908A5030620040 @default.
• W2071320908 hasAuthorship W2071320908A5040917727 @default.
• W2071320908 hasAuthorship W2071320908A5070261883 @default.
• W2071320908 hasAuthorship W2071320908A5072346701 @default.
• W2071320908 hasAuthorship W2071320908A5084607034 @default.
• W2071320908 hasConcept C126322002 @default.
• W2071320908 hasConcept C168481208 @default.
• W2071320908 hasConcept C197934379 @default.
• W2071320908 hasConcept C2777119127 @default.
• W2071320908 hasConcept C2778375690 @default.
• W2071320908 hasConcept C2778541695 @default.
• W2071320908 hasConcept C42219234 @default.
• W2071320908 hasConcept C71924100 @default.
• W2071320908 hasConceptScore W2071320908C126322002 @default.
• W2071320908 hasConceptScore W2071320908C168481208 @default.
• W2071320908 hasConceptScore W2071320908C197934379 @default.
• W2071320908 hasConceptScore W2071320908C2777119127 @default.
• W2071320908 hasConceptScore W2071320908C2778375690 @default.
• W2071320908 hasConceptScore W2071320908C2778541695 @default.
• W2071320908 hasConceptScore W2071320908C42219234 @default.
• W2071320908 hasConceptScore W2071320908C71924100 @default.
• W2071320908 hasIssue "4" @default.
• W2071320908 hasLocation W20713209081 @default.
• W2071320908 hasLocation W20713209082 @default.
• W2071320908 hasOpenAccess W2071320908 @default.
• W2071320908 hasPrimaryLocation W20713209081 @default.
• W2071320908 hasRelatedWork W1615607778 @default.
• W2071320908 hasRelatedWork W2026440836 @default.
• W2071320908 hasRelatedWork W2071320908 @default.
• W2071320908 hasRelatedWork W2111791648 @default.
• W2071320908 hasRelatedWork W2114905304 @default.
• W2071320908 hasRelatedWork W2119553926 @default.
• W2071320908 hasRelatedWork W2136100212 @default.
• W2071320908 hasRelatedWork W2163999270 @default.
• W2071320908 hasRelatedWork W3090177545 @default.
• W2071320908 hasRelatedWork W4285394174 @default.
• W2071320908 hasVolume "45" @default.
• W2071320908 isParatext "false" @default.
• W2071320908 isRetracted "false" @default.
• W2071320908 magId "2071320908" @default.
• W2071320908 workType "article" @default.